Article
Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study.
Journal of gastroenterology and hepatology - 1 Jul 2012
Ogawa Eiichi, Furusyo Norihiro, Kajiwara Eiji, Takahashi Kazuhiro, Nomura Hideyuki, Tanabe Yuichi, Satoh Takeaki, Maruyama Toshihiro, Nakamuta Makoto, Kotoh Kazuhiro, Azuma Koichi, Dohmen Kazufumi, Shimoda Shinji, Hayashi Jun
Abstract excerpt
BACKGROUND AND AIMS: Pegylated interferon (PEG-IFN) α-2b and ribavirin (RBV) treatment of chronic hepatitis C virus (HCV) infection is associated with a substantially elevated risk of discontinuation. The aim of this study is to evaluate the reason for premature discontinuation during PEG-IFN α-2b and RBV treatment due to adverse effects in patients with chronic HCV infection. METHODS: A total of 2871 Japanese...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
